vimarsana.com

Ose Immunotherapeutics Sa News Today : Breaking News, Live Updates & Top Stories | Vimarsana

OSE Immunotherapeutics SA: Four Poster Presentations at 2022 ASCO Annual Meeting Seite 1

07.06.2022 - Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and its clinical partners GERCOR, ARCAGY-GINECO and the FoRT Foundation (Fondazione Ricerca Traslazionale), presented four posters featuring neoepitope specific . Seite 1

Ose immunotherapeuticsOse immunotherapeutics sa

OSE Immunotherapeutics To Present at Immuno-Oncology Summit Europe and at Tumor Myeloid-Directed Therapies Summit In London and Boston

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

United statesUnited kingdomCity ofElise chiffoleauThomas guillotFlorence portejoieGuillaume van renterghemDarren oplandNantes university hospitalLifesci communicationsNantes university at hospitalVeloxis pharmaceuticals incBoehringer ingelheimOncology summit europeMyeloid directed therapies summitTranslational immunology

OSE Immunotherapeutics Announces New European Patent Granted Covering CLEC-1, Novel Myeloid Immune Checkpoint Target For Cancer Immunotherapy

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

United statesElise chiffoleauNicolas poirierDominique costantiniThomas guillotFlorence portejoieGuillaume van renterghemDarren oplandNantes university hospitalEuropean patent officeNantes university at hospitalBoehringer ingelheimLifesci communicationsVeloxis pharmaceuticals incChief executive officerChief scientific officer

OSE Immunotherapeutics Announces the Appointment of Dominique Costantini as Interim CEO Following the Departure of Alexis Peyroles

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Alexis peyrolesDominique costantiniNantes university hospitalBoehringer ingelheimChief executiveChief executive officerLaurence de schoulepnikoffChief business officerChief operating officerNon small cell lung cancerExpansion phaseUniversal registration documentCoronavirus pandemicOse immunotherapeutics saGlobe newswire

vimarsana © 2020. All Rights Reserved.